Drug Profile


Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; SAVAYSA

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Embolism; Stroke; Venous thromboembolism
  • Registered Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism
  • Phase I Venous thrombosis

Most Recent Events

  • 01 Dec 2016 Registered for Atrial fibrillation in Thailand (PO) (Daiichi Sankyo pipeline, February 2017)
  • 01 Dec 2016 Registered for Venous thromboembolism in Thailand (PO) (Daiichi Sankyo pipeline, February 2017)
  • 22 Nov 2016 Efficacy data from the phase III ENGAGE-AF-TIMI-48 trial in Atrial fibrillation presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top